Literature DB >> 9365148

Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.

R J Brummer1, B J Geerling, R W Stockbrügger.   

Abstract

In a placebo-controlled, double-blind, multiple crossover study, the initial and chronic acid-inhibitory effect of lansoprazole 30 mg, orally administered half an hour before breakfast or immediately after breakfast, and of omeprazole 20 mg, administered postprandially, respectively, was investigated in 16 healthy volunteers, using ambulant 24-hr intragastric pH monitoring. On the first day of medication, only preprandially administered lansoprazole reduced acid secretion significantly (median 24-hr pH 3.0; P < 0.05). On day 15, the median 24-hr intragastric pH of lansoprazole preprandial (pH 4.1), lansoprazole postprandial (pH 4.3), and omeprazole postprandial (pH 3.3), respectively, differed significantly (P < 0.05) from placebo (pH 1.2). It is concluded that the interaction between food intake and lansoprazole administration only is important at the start of oral therapy. Lansoprazole taken before breakfast is effective even on the initial day of treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365148     DOI: 10.1023/a:1018891106425

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects.

Authors:  C Cederberg; K Röhss; P Lundborg; L Olbe
Journal:  Scand J Gastroenterol       Date:  1993-02       Impact factor: 2.423

2.  Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.

Authors:  D W Burget; S G Chiverton; R H Hunt
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

3.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 4.  Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

Authors:  N J Bell; R H Hunt
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

5.  Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

Authors:  S Bruley des Varannes; P Levy; S Lartigue; F Dellatolas; M Lemaire; J P Galmiche
Journal:  Aliment Pharmacol Ther       Date:  1994-06       Impact factor: 8.171

Review 6.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

7.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.

Authors:  P J Prichard; N D Yeomans; G W Mihaly; D B Jones; P J Buckle; R A Smallwood; W J Louis
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

8.  Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.

Authors:  E F Verdú; R Fraser; D Armstrong; A L Blum
Journal:  Scand J Gastroenterol       Date:  1994-12       Impact factor: 2.423

9.  Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.

Authors:  C J Hawkey; R G Long; K D Bardhan; K G Wormsley; K M Cochran; J Christian; I K Moules
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

10.  Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.

Authors:  C Larson; N J Cavuto; D A Flockhart; R B Weinberg
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

View more
  4 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Authors:  Yinglian Xiao; Shutian Zhang; Ning Dai; Guijun Fei; Khean-Lee Goh; Hoon Jai Chun; Bor-Shyang Sheu; Chui Fung Chong; Nobuo Funao; Wen Zhou; Minhu Chen
Journal:  Gut       Date:  2019-08-13       Impact factor: 23.059

Review 4.  Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review.

Authors:  Agnieszka Wiesner; Małgorzata Zwolińska-Wcisło; Paweł Paśko
Journal:  Int J Environ Res Public Health       Date:  2021-03-29       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.